StockStory.org on MSN
Pharmaceuticals stocks Q4 highlights: Ocular Therapeutix (NASDAQ:OCUL)
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...
Looking to invest in biotech stocks? Learn what they are, explore top options, and find out how to get started in this fast-growing, exciting industry.
Everyone should save money for retirement, since programs such as Social Security aren't meant to replace workers' entire ...
Investor's Business Daily on MSN
Vertex Pharmaceuticals joins elite list of stocks with 95-plus composite rating
Vertex Pharmaceuticals saw an improvement in its IBD SmartSelect Composite Rating Wednesday, from 94 to 96.
Some artificial intelligence (AI)-focused companies have delivered exceptional returns over the past few years, but some ...
Vertex Pharmaceuticals shares surged Tuesday after the company posted promising results from a clinical trial of a drug to treat kidney disease.
Sun Pharma is transitioning its US business from low-margin generics to high-value specialty and innovative therapies.
ORLANDO, FL / ACCESS Newswire / February 27, 2026 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, ...
Over the next 5 years, Gland Pharma plans to invest approximately Rs 20 bn in capex, primarily towards BFS and ophthalmic lines as well as capex towards CDMO contracts. Brownfield expansions will ...
The company's pipeline features almost 40 programs in late-stage clinical testing. These clinical trials are testing new drug candidates and seeking additional approvals for drugs such as Tremfya.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results